Senseonics (NYSE:SENS) shares were up after hours today on second-quarter results that came up shy of the consensus forecast. The Germantown, Maryland-based continuous glucose monitoring technology developer posted profits of $103.9 million, or 22¢ per share, on sales of $3.7 million for the three months ended June 30, 2022, for a massive bottom-line gain from […]
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
Wells Fargo downgraded Tandem Diabetes Care (Nasdaq:TNDM) as competitors apply pressure to the automated insulin delivery technology developer. According to SeekingAlpha, analysts led by Larry Biegelsen moved Tandem from “Overweight” to “Underweight” due to bullish expectations on Wall Street as the company’s competition, including Insulet and Medtronic, come to the fore. The street responded in kind, with shares […]
Abbott, WeightWatchers partner on diabetes care
Abbott (NYSE:ABT) announced that it entered into a strategic partnership with WeightWatchers to help people living with diabetes. The companies will work together to integrate WeightWatchers’ diabetes-tailored weight management program with Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) products to help them better understand and manage their diabetes and weight. According to a news release, the […]
Insulet up on Q2 sales beat, raised full-year guidance
Insulet (Nasdaq:PODD) stock is up today — a day after releasing Q2 results that blew past the consensus revenue forecast. The Acton, Massachusetts–based automated insulin delivery technology developer yesterday evening posted losses of $35 million, or 50¢ per share, on sales of $299.4 million for the three months ended June 30, 2022, for a $10 million […]
Tandem sinks on Q2 misses, slashed sales guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a bit hit after hours on second-quarter results that missed the consensus forecast. Shares of TNDM were down 7.2% at $64 per share after the market closed, which was when it released its quarterly results. The San Diego-based automated insulin delivery technology developer posted losses of $15.1 million, or 24¢ […]
Insulet begins full market launch for Omnipod 5
Insulet (Nasdaq:PODD) announced today that it commenced the full market launch for its next-generation Omnipod 5 insulin delivery system. The Omnipod 5 automated insulin delivery (AID) system has now been made fully available through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes. Acton, Massachusetts-based Insulet received FDA clearance […]
How Medtronic aims to address health inequities in diabetes
Fueled by personal experience, Maribel Baker leads Medtronic’s diabetes business toward improving health equity. At 15 years old, Maribel Baker’s life was in the balance. While growing up in Panama, Baker had to undergo leg surgery because she was born with one leg shorter than the other. Following the surgery, she learned that she had […]
Dexcom to update next-gen G7 software, delaying FDA clearance, launch timelines
The CEO of Dexcom (Nasdaq:DXCM) said today that the company’s regulatory path for the next-generation G7 has been slightly delayed. Speaking on the continuous glucose monitor (CGM) maker’s second-quarter earnings call, Dexcom Chair, President and CEO Kevin Sayer explained that the company has — based on feedback from the FDA — been tweaking the software of its next-generation […]
Dexcom stock dips on missed Q2 projections with broader G7 launch ‘in coming weeks’
Dexcom (Nasdaq:DXCM) shares took a hit after hours today on second-quarter results that came up shy of the consensus forecast. Shares of DXCM were down 7.2% at $80.69 after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 2.4%. Get the full story at […]
6 drug delivery innovations you need to know
From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops. Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies. More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With some […]
DyAnsys wins FDA clearance for neurostimulator that treats diabetic neuropathic pain
DyAnsys recently announced that its First Relief neurostimulation device received FDA clearance to treat pain from diabetic peripheral neuropathy. Palo Alto, California-based DyAnsys designed the wearable device, placed on the ear, to administer continuous pulses of low-level electrical current over several days, offering multiple treatments of up to 56 days for symptomatic relief of chronic, […]